IMFINZI (durvalumab) Regimen Reduced Risk of Progression, Recurrence or Death by 29% in Early-Stage Gastric Cancer vs. Chemotherapy Alone in MATTERHORN Phase III Trial
June 03, 2025
June 03, 2025
WILMINGTON, Delaware, June 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
IMFINZI (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years
First and only immunotherapy to demonstrate statisti . . .
* * *
IMFINZI (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
Two-thirds (67.4%) of patients treated with IMFINZI-based perioperative regimen remained event-free at two years
First and only immunotherapy to demonstrate statisti . . .